No­var­tis ad­justs busi­ness unit names in prepa­ra­tion for San­doz gener­ics and biosim­i­lars spin­off

No­var­tis is mod­i­fy­ing its busi­ness units’ names to re­flect its full fo­cus on in­no­v­a­tive med­i­cines when San­doz spins off with gener­ics and biosim­i­lars lat­er this year.

Two di­vi­sions will drop the words “in­no­v­a­tive med­i­cines” from their names — go­ing from In­no­v­a­tive Med­i­cines In­ter­na­tion­al to In­ter­na­tion­al and from In­no­v­a­tive Med­i­cines US to sim­ply US. Re­search & ear­ly de­vel­op­ment will now be called Bio­med­ical Re­search, drop­ping one word from its cur­rent In­sti­tutes for Bio­Med­ical Re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER